Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: A systematic review

Haru Iino, Masayuki Hashiguchi*, Satoko Hori
Division of Drug Informatics, Keio University Faculty of Pharmacy, Tokyo, Japan

* hashiguchi-ms@pha.keio.ac.jp

Abstract

Background
Decision-making in healthcare policy involves assessing both costs and benefits. In determining the cost-effectiveness (CE) threshold, willingness to pay (WTP) per quality-adjusted life year (QALY), GDP per capita, and other factors are important. However, the relationship between WTP/QALY or GDP per capita and the CE threshold is unclear. It is important to clarify the relationship between WTP/QALY and GDP to provide a clear basis for setting the CE threshold.

Objective
The purpose of this study was to compare WTP/QALY and GDP per capita, and to develop a new CE threshold range based on WTP using GDP per capita. The relationship between WTP/QALY and healthy life expectancy (HALE) was also investigated.

Methods
We searched MEDLINE, EMBASE and Web of Science from 1980/01/01 to 2020/12/31 using the following selection criteria (latest search: Dec 2021): 1, studies that estimated WTP/QALY; 2, the general population was surveyed; 3, the article was in English. From the collected articles, we obtained average values of WTP/QALY for various countries and compared WTP/QALY with GDP per capita. The correlation between WTP/QALY and HALE was also examined.

Results
We identified 20 papers from 17 countries. Comparison of mean WTP/QALY values with GDP per capita showed that most WTP/QALY values were in the range of 0.5–1.5 times GDP per capita, though the median values were less than 0.5 times. Comparison of WTP/QALY with HALE showed a statistically significant positive correlation when Taiwan was excluded as an outlier.
Conclusions

Our results suggest a CE threshold range of 0.5–1.5 times GDP per capita is appropriate but lower than the WHO-recommended range of 1–3 times. The correlation between WTP/QALY and HALE suggests that investment in healthcare is reflected in an increased healthy life expectancy. Since WTP is based on consumer preferences, this range could be used to set a generally acceptable criterion.

Introduction

Improvements in medical technology and sanitation have significantly prolonged human life expectancy. However, the development of new health technologies is expensive, and the cost of pharmaceuticals is also increasing. As a result, health care spending as a percentage of gross domestic product (GDP) has been increasing globally, and there is a debate as to how available funds should best be spent [1]. Health technology assessment (HTA) has been used to consider both effectiveness and cost, since medical resources are finite and, in many cases, publicly financed through taxation [2].

Cost-effectiveness analysis in HTA is conducted by calculating the incremental cost-effectiveness ratio and determining cost-effectiveness based on the cost-effectiveness threshold (CE threshold) [3]. In particular, when determining the threshold for insurance reimbursement, GDP per capita or willingness to pay per quality-adjusted life year (WTP/QALY), which can be used to calculate the cost of general health conditions. This may be used as a reference to set the same threshold for all items rather than for specific diseases. The CE threshold has an important role in HTA, as it can be used to determine whether reimbursement is appropriate.

The World Health Organization (WHO) recommends a threshold of one to three times the GDP per capita for the cost of investing in one disability-adjusted life year (DALY), which is widely known and often cited when discussing CE thresholds. However, the rationale for the upper limit of three times is not well defined, and is insufficient as a basis for decision-making [4,5]. Since the rationale for a criterion based on GDP per capita is unclear, Wood et al. (2016) estimated a range of thresholds based on opportunity cost, resulting in a range of 1–51% of GDP per capita for low- and middle-income countries and 18–71% for middle- and high-income countries [5].

One way to determine the C/E threshold is to use the opportunity cost approach, that is, the value of health that would have to be given up by investing the healthcare budget in a healthcare service, or to measure the willingness to pay (WTP) for a year of staying healthy [6]. The setting of thresholds can affect access to health care and the use of public funds. For this reason, we think it is better to reflect people’s intentions/preferences in setting the threshold. The WTP approach measures people’s preferences, so that by focusing on this approach, we may find evidence for setting a threshold that is more generally acceptable to people.

In WTP-based methods, the WTP for one quality adjusted life year (QALY) is usually used. In addition, the threshold is often set by referring to surveys of the general health status for a population, rather than specific health conditions, and where systematic reviews of these surveys have been reported [7–10]. From these studies, it is known that WTP is affected by many factors, including survey methods, survey population, and calculation methods, but few studies have examined the relationship between GDP per capita and WTP/QALY. Furthermore, even in those studies, there are large differences in study design, for example whether the survey is
based on stated or revealed preferences, and also in evaluation, and thus the quality of the results is insufficient [7,9].

Therefore, the purpose of this study was to clarify the appropriate range of GDP per capita based on WTP/QALY values by organizing the available data using our criteria. In this study, we will not only summarize the ratio of WTP/QALY to GDP per capita, but also identify the range within which most WTP/QALY values fit. That range can be used as a guide for threshold setting even in countries that have not conducted WTP surveys before. Also, since this range is based on consumer preferences, it should be possible to set a threshold that the general population would regard as acceptable.

We also examined the correlation between Healthy Life Expectancy (HALE) and WTP/QALY to investigate whether there is a relationship between WTP/QALY and people’s health status. HALE is the value of life expectancy weighted by health status. It indicates the expected life expectancy assuming overall survival in a completely health state.

In this article, we often compare cost/DALY and cost/QALY. The WHO criteria are based on DALYs, while the values calculated by WTP and many health economic studies are based on QALYs. Although they are different in calculations and definitions, their meaning is the same: survival in a healthy state [11]. Cost/QALY and Cost/DALY both indicate the cost of gaining one perfectly healthy life year and can therefore be validly compared [12].

**Methods**

**Article search**

We conducted a systematic search using MEDLINE, EMBASE and Web of Science. The search terms used were "quality adjusted life year" "quality adjusted life years" "disability adjusted life year" "disability adjusted life years" "cost benefit analysis" and "willingness to pay" and the search period was specified as between 1980/01/01 and 2020/12/31 based on publication date. For instance, the detailed search in MEDLINE is ("quality adjusted life year"[All Fields] OR "quality adjusted life years"[All Fields] OR "disability adjusted life year"[All Fields] OR "disability adjusted life years"[All Fields]) AND "cost benefit analysis"[All Fields] AND "willingness to pay"[All Fields] AND 1980/01/01:2020/12/31[Date—Publication]. Articles retrieved were reviewed based on the following criteria: 1, studies that estimated WTP/QALY; 2, the general population was surveyed; 3, the article was in English. Database searches were conducted from the start of the research until December 2021. The search, removal of duplicates, and initial screening were done by a single author (HI). Screening of potentially compatible references was done independently by two authors (HI, HM). If there was any disagreement, the third author (SH) provided advice. A flow diagram of the selection procedure is shown in Fig 1. The searching process is shown in detail in Supporting information (S1 File). Management of literature and removal of duplicates were done by Mendeley Desktop Version 1.19.8 (Mendeley Ltd).

**Data collection and extraction**

The value of statistical life (VSL) method shows revealed preference against the risk of death, and the calculated value is higher than values obtained using other methods [8,13]. There are also some reports that values calculated using the visual analog scale (VAS) have a high ceiling effect, and that the correlation with health status is low to begin with, so that reliability is questionable. Therefore, in this study, we excluded VSL values and values measured using VAS only [14–16]. However, we did not exclude the case where VAS was used in conjunction with EQ-5D.
Data integration, analysis

WTP/QALY values were converted to international dollars in 2019 using purchasing power parity (PPP) and the inflation rate; PPP values were taken from the International Monetary Fund database, and the US Inflation Calculator was used to adjust for inflation [17,18]. WTP/QALY was calculated using Euro, but where the country’s currency was not Euro, it has been converted using PPP value as EU. The EU PPP was taken from the Organization for Economic
Co-operation and Development (OECD) [19]. All the conversion rates are survey year values. If the survey year was unknown, the publication year of the report was used.

When the mean and median of WTP/QALYs were reported together in an article, they were analyzed separately. In cases where there were multiple mean and median values for a country, the respective averages were calculated and used as representative values for that country. (For example, suppose that for one country there are three means [1000, 2500, 2500] and two medians [1000, 2000] available; in that case, the country would have a mean of 2000 and a median of 1500.) Where a unique calculated value of WTP/QALY that is neither the mean nor the median was shown, it was treated as being equivalent to the mean value. In cases where WTP/QALYs were calculated for two populations (patients and general people), only the results for the general people were used, not the results for patients.

For comparison between GDP per capita and WTP/QALY, we plotted the respective values and drew lines representing one and three times GDP per capita, the range of threshold values recommended by the WHO [4]. Then, $n$ times lines were extrapolated such that the WTP/QALY values for countries were fitted appropriately. Correlation analysis was performed for WTP/QALY and HALE, and GDP per capita was taken from the International Monetary Fund database as converted to international dollars according to PPP [20]. HALE data were taken from the WHO website, except for Taiwan, where the average for men and women was obtained from the Global Burden of Disease Study 2017 [21,22]. In addition, we cite the GNI-based classification presented by the World Bank as a tool for classifying countries [23]. Correlation analysis was performed using IBM SPSS Statistics for Mac ver26 (IBM SPSS Inc., Chicago, USA). Cook’s distance and DFFITS were calculated as statistical diagnostics for outliers in the regression. Cook’s distance and DFFITS were calculated using Python 3.7 and its module statsmodels v0.13.1[24,25]. Analysis of the data was performed by one author (IH) and the methods and results were reviewed independently by two authors (MH, SH). This review was not registered in the registry. Also, the protocol was not prepared.

**Results**

The search (search date: March 2021) yielded 20 articles that met the final selection criteria (Fig 1). From the articles, we obtained 233 data on the mean WTP/QALY for 17 countries, including 106 median WTP/QALYs in 16 countries. The obtained articles and WTP/QALY values are summarized in Table 1. All the collected and processed data are shown in the Supporting Information (S1 Table, S1 Fig). Some examples of studies that were excluded by screening are as follows. A study by LauraVallejo-Torres (2016) calculated WTP/QALYs, but the values were calculated using a historical database and did not actually investigate WTP [26]. The study by Jesus Martín-Fernández (2014) targets patients rather than the general population [27]. Such studies do not fit the criteria for adoption and are therefore not included in this study.

Comparison of the mean WTP/QALY with GDP per capita shows that 41.2% (7/17) of the countries were located in the WHO-recommended range of 1 to 3 times GDP per capita (red line). When the criterion was set to 0.5 to 2 times GDP per capita (yellow line), fifteen out of seventeen countries (88.2%) were located in the range (Fig 2). Within 0.5 to 1.5 times GDP per capita, fourteen out of seventeen countries (82.4%) were located in the range. As regards the median, in twelve out of sixteen countries (75%), the values were distributed below 0.5 times GDP per capita (Fig 3).

We found no correlation between WTP/QALY and HALE ($r = 0.246$). Cook’s distance and DFFITS were calculated, and we confirmed that Taiwan was an outlier (detailed data and code...
Table 1. List of WTP/QALY values from the literature [28–46].

| Country | Author                          | Survey year | Sample size (total respondents on the article) | perspective | Scenario type | QALY measuring method | Number of WTP/ QALY mean estimates (median) | Currency unit | Range of WTP/QALY mean (median) | average of WTP/ QALY USD2019 adjusted Value (median) | Average of WTP/ QALY mean USD2019 Value (median) | GNI income categories          |
|---------|--------------------------------|-------------|-----------------------------------------------|-------------|---------------|----------------------|---------------------------------------------|---------------|----------------------------------|--------------------------------------------------|--------------------------------------------------|-----------------------------|
| Australia | Shiroiwa et al. (2010) [28]    | 2008        | 1000 (5620)                                   | Individual and Societal | General health  | -                     | 3(1)                                       | AUD           | 64000–89,000 (36,000)             | 77000 (36000)                                                      | 62198 (30,146)                   | High-income                 |
| China    | Zhao et al. (2011) [29]        | 2009        | 632                                           | Individual and Societal | Chronic prostatitis and General health (Own current health status) | EQ-5D, SF-6D | 2                     | USD 4711–5,012                           | 4,862                                      | 5,525                                              | 5,525 (Upper-middle-income)                 |
| Denmark  | Gyld-hansen et al. (2003) [30] | 2001        | 3201                                          | Individual     | General health | EQ-5D                | 2                                          | DKK           | 74109–88,000                    | 81,055 (15,820)                                                       | 33695 (12,248)                   | High-income                 |
|          | Gyld-hansen et al. (2012) [16] | N/A         | 1724                                          | Individual     | General health | EQ-5D, TTO          | 6(2)                                       | EUR           | 2740–44,565 (60,770–92,307)       | 22571 (76,539)                                                | 31176 (11,034)                   |                                                            |
|          | Robinson et al. (2013) [31]   | 2008        | 2637 (21896)                                  | Individual     | General health | EQ-5D, TTO, SG      | 8(8)                                       | EUR           | 24796–57,389 (57,49–15,409)       | 36722 (9,257)                                        | 54089 (13,462)                   |                                                            |
| France   | Robinson et al. (2013) [31]   | 2008        | 2674 (21896)                                  | Individual     | General health | EQ-5D, TTO, SG      | 8(8)                                       | EUR           | 11317–26,890 (2745–4,374)         | 19954 (3,520)                                           | 29251 (4,832)                   | High-income                 |
| Greece   | Afentoula M et al. (2020) [32] | 2019        | 528                                           | Individual     | General health | EQ-5D                | 5(5)                                       | EUR           | 11176–27,487 (2167–6070)          | 19952 (3222)                                         | 36276 (5859)                    | High-income                 |
| Hungary  | Robinson et al. (2013) [31]   | 2008        | 2287 (21896)                                  | Individual     | General health | EQ-5D, TTO, SG      | 8(8)                                       | EUR           | 10938–26,132 (3081–7,671)         | 17945 (4,975)                                         | 26432 (7,235)                   | High-income                 |
| Japan    | Shiroiwa et al. (2010) [28]   | 2008        | 1114 (5620)                                   | Individual and Societal | General health | -                     | 3(1)                                       | JPY           | 5000000–6,400,000 (3,100,000)     | 5600000 (3,100,000)                                           | 57009 (31,559)                   | High-income                 |
|          | Shiroiwa et al. (2013) [33]   | 2011        | 2283                                          | Individual     | General health | EQ-5D                | 1(1)                                       | USD           | 50000 (50,000)                   | 50000 (50,000)                                           | 56828 (56,828)                  |                                                            |
|          | Igarashi et al. (2019) [34]   | N/A         | 1000                                          | Individual and Societal | General health | EQ-5D                | 9                                          | JPY           | 2600000–14,900,000               | 5,374,444 (52,898)                                                |                                                            |                                                            |

(Continued)
| Country         | Author                   | Survey year | Sample size (total respondents on the article) | perspective | Scenario type | QALY measuring method | Number of WTP/QALY mean estimates (median) | Currency unit | Range of WTP/QALY mean (median) | Average of WTP/QALY mean USD2019 adjusted Value (median) | Average of WTP/QALY mean USD2019 Value (median) | GNI income categories |
|-----------------|--------------------------|-------------|-----------------------------------------------|-------------|---------------|----------------------|------------------------------------------|---------------|----------------------------------|----------------------------------------------------------|----------------------------------------------------------|---------------------|
| Netherland      | Bobinac et al. (2010)    | 2008        | 1091                                          | Individual  | General health| EQ-5D                | 1                                        | EUR           | 24,500                          | 64,925                                                   | 117,380                                                  | High-income         |
|                 | Bobinac et al. (2012)    | N/A         | 1004                                          | Societal    | General health| EQ-5D                | 4                                        | EUR           | 52,200–83,200                   | 85,567 (32,767)                                           | 117,380 (44,949)                                           |                     |
|                 | Bobinac et al. (2013)    | N/A         | 1004                                          | Individual  | General health| EQ-5D                | 6(3)                                     | EUR           | 55,400–113,200 (23,500–37,900)    | 85,567 (32,767)                                           | 117,380 (44,949)                                           |                     |
|                 | Bobinac et al. (2013)    | 2010        | 1091                                          | Individual  | General health| EQ-5D                | 29                                       | EUR           | 1,200–21,400                    | 9,162                                                   | 12,637                                                    |                     |
|                 | Robinson et al. (2013)   | 2008        | 2510 (21896)                                  | Individual  | General health| EQ-5D, TTO, SG     | 8(8)                                     | EUR           | 157,38–27,418 (3415–7,904)       | 22022 (5,039)                                            | 30873 (6,975)                                              |                     |
| Norway          | Robinson et al. (2013)   | 2008        | 2020 (21896)                                  | Individual  | General health| EQ-5D, TTO, SG     | 8(8)                                     | EUR           | 21,602–41,298 (7621–15,472)      | 31956 (9,389)                                            | 47068 (13,654)                                             | High-income         |
| Poland          | Robinson et al. (2013)   | 2008        | 2173 (21896)                                  | Individual  | General health| EQ-5D, TTO, SG     | 8(8)                                     | EUR           | 18,601–40,023 (3611–10,748)      | 28,368 (6,788)                                           | 41,784 (9,872)                                             | High-income         |
| Republic of Korea | Shiroiwa et al. (2010)  | 2008        | 1000 (5620)                                   | Individual and Societal  | General health| -                  | 3(1)                                     | KRW          | 68,000,000–79,000,000 (46,000,000) | 720,000,000 (46,000,000)                                      | 103,641 (66,644)                                           | High-income         |
|                 | Song HJ et al. (2018)    | 2015        | 507                                           | Individual   | General health | EQ-5D                | 4                                        | KRW          | 15,000,000–35,000,000            | 24,750,000,000                                           | 31,078                                                   |                     |
| Spain           | Pintto-Prades et al. (2009) | N/A       | 892                                           | Individual   | General health | EQ5D, SG             | 37                                       | EUR           | 45,85–123,724                   | 30,385                                                   | 48,757                                                   | High-income         |
|                 | Robinson et al. (2013)   | 2008        | 2679 (21896)                                  | Individual  | General health| EQ-5D, TTO, SG     | 8(8)                                     | EUR           | 256,29–52,876 (6671–12,869)      | 367,80 (8,089)                                            | 590,19 (13,171)                                            |                     |
| Sweden          | Robinson et al. (2013)   | 2008        | 2604 (21896)                                  | Individual  | General health| EQ-5D, TTO, SG     | 8(8)                                     | EUR           | 169,08–35,200 (3235–7,842)       | 267,89 (4,803)                                            | 394,29 (6,985)                                             | High-income         |
|                 | Sund et al. (2018)       | 2014        | 1400                                          | Individual   | General health | EQ-5D                | 1                                        | SEK           | 280,000                        | 280,000                                                  | 34,636                                                   |                     |
| Taiwan          | Shiroiwa et al. (2010)   | 2008        | 504 (5620)                                    | Individual and Societal | General health | -                  | 3(1)                                     | NT$          | 180,000–2,100,000 (1,400,000)    | 193,333,33 (140,000)                                      | 140,840 (55,973)                                           | High-income         |

(Continued)
| Country   | Author                        | Survey year | Sample size | perspective | Scenario type                        | QALY measuring method | Number of WTP/QALY mean estimates (median) | Currency unit | Range of WTP/QALY mean (median) | average of WTP/QALY USD2019 adjusted Value (median) | WTP/QALY mean USD2019 Value (median) | Average of WTP/QALY mean USD2019 Value (median) | GNI income categories |
|-----------|-------------------------------|-------------|-------------|-------------|--------------------------------------|------------------------|---------------------------------------------|--------------|---------------------------------|-----------------------------------------------|------------------------------------------|-----------------------------------------------|---------------------|
| Thailand  | Thavorncharoenasap et al. (2013) [42] | N/A         | 4320        | Individual  | General health                       | EQ-5D                 | 16(16)                                      | Baht         | 72238–350,161 (38396–150,376) | 169841 (76,211)                                | 15215 (6,827)                              | 15938 (6,827)                                   | Upper-middle-income |
|           |                               | 2008        | 1191        | Individual  | Blindness, paraplegia and allergies  | TTO, VAS               | 12                                          | Baht         | 26000–285,000                  | 109,500                                  | 10,908                                    |                                                 |                     |
|           | Nimdet et al. (2015) [44]     | 2013        | 600         | Individual  | General health                       | EQ-5D                 | 1                                           | Baht         | 243,120                        | 243,120                                  | 21,691                                    |                                                 |                     |
|           |                               | 2008        | 1002 (5620) | Individual  | General health                       | -                      | 3(1)                                        | GBP          | 23000–38,000 (12,000)          | 29000 (12000)                             | 49193 (20,621)            | 41723 (13,630)                                   | High-income |
|           | Robinson et al. (2013) [31]    | 2008        | 2312 (21896)| Individual  | General health                       | EQ-5D, TTO, SG        | 8(8)                                        | EUR          | 13228–29,308 (3064–6,775)      | 20193 (3,959)                                      | 34253 (6,639)                          |                                                 |                     |
|           |                               | 2005        | 193         | Individual  | Osteoarthritis and general health    | SG, TTO               | 6                                           | USD          | 2844.1–5,690                   | 3,981                                    | 5,750                                    | 46265 (26,259)                                   | High-income |
|           | Lieu et al. (2009) [46]       | 2005        | 478         | Individual  | Shingles and hepatic neuralgia      | TTO                   | 1(1)                                        | USD          | 33000 (12,000)                 | 33000 (12000)                            | 43198 (15,708)                           |                                                 |                     |
|           | Shiroiwa et al. (2010) [28]   | 2008        | 1000 (56200)| Individual  | General health                       | -                      | 3(1)                                        | USD          | 62000–96,000 (31,000)          | 75667 (31000)                           | 89848 (36,810)                           |                                                 |                     |

TTO, Time-trade off; SG, Standard gamble.

https://doi.org/10.1371/journal.pone.0266934.t001
are available in Supporting information (S2 Table, S2 File)). When Taiwan was excluded, a statistically significant positive correlation was observed (Fig 4, r = 0.636, p = 0.008).

Discussion

To make effective use of medical resources, policymakers in each country need to have a policy regarding their proper allocation. Cost-effectiveness evaluation is necessary for decision-making. In this study, we examined GDP per capita and HALE as indicators of the CE threshold. A comparison of the average WTP/QALY with GDP per capita showed that the values of WTP/QALY for most countries were located in the range of 0.5–1.5 times GDP per capita.

According to the WHO-recommended threshold, less than the GDP per capita is rated as "highly effective" and from one to three times GDP per capita as "cost-effective" [4]. The former assessment is based on the assumption that if an intervention can produce one QALY per year at the cost of less than the GDP per capita, the resulting value-added will exceed the cost of the investment [4,47].
In this study, the mean values of WTP/QALYs were distributed well below the WHO upper threshold (Fig 2). Therefore, setting a CE threshold based on the WHO criteria may give the impression of being relatively expensive to the general population. Moreover, expensive new drugs are being launched rapidly, and thus the cost of gaining a new QALY in developed countries might be increasing. In this case, the cost of gaining additional health is likely to be higher than the WTP that people anticipate. Especially in health care, there is a large asymmetry of information, which may lead to a discrepancy between the actual threshold and the WTP.

Countries in the upper-middle-income group tend to have lower WTP/QALYs than those in the high-income group. When healthcare expenditure is low, the law of diminishing marginal utility suggests that the health value gained may be relatively high in relation to the cost. In such countries, the criterion of 0.5–1.5 times GDP shown in this study may be potentially suitable. If $\Delta \text{Cost}/\Delta \text{QALY}$ is less than the GDP per capita, the cost-effectiveness is excellent. However, if the CE threshold is set to less than the GDP per capita, the use of health technologies that theoretically have a higher return than the cost could be restricted. Therefore, an actual CE threshold of 1–1.5 times GDP per capita is considered to be an appropriate range.
On the other hand, there is an example of a threshold of less than the GDP per capita. In Thailand, a threshold of 0.8 times GDP (100,000 baht) was set in 2007 when the list of essential medicines was created, and this threshold is used for price adjustment [4,43]. This criterion was set based on gross national income (GNI), and was not intentionally set below the GDP per capita [48]. This policy led to price reductions of 72% for tenofovir and 69% for oxaliplatin in Thailand [49]. The prices after these reductions are about the same as in Japan, but are relatively high considering the GDP ratio. This suggests that the cost before the price reduction was high, so the price adjustment based on the threshold may have worked appropriately [50,51].

In the comparison of median WTP/QALYs and GDP per capita, most values were in the range of 0.5 times or less. Furthermore, the median value was lower than the mean value in all countries. This result is similar to that reported by Song et al (2018) and implies that the distribution of WTP is skewed with a long tail to the right [39]. Several previous studies have reported that WTP has larger values when people’s income is higher. Considering that the distribution of WTP has a similar pattern to that of income, the median value is expected to be lower than the mean [4,28]. The median value would be useful in situations where the burden of medical expenses on individuals is large. In contrast, from the government’s perspective, the

---

**Fig 4. GDP per capita plotted against WTP/QALY by country.** Taiwan was excluded as an outlier. Pearson’s correlation analysis was performed, and a statistically significant correlation was found ($r = 0.636, p = 0.008$).

https://doi.org/10.1371/journal.pone.0266934.g004
impact of the total cost on the budget is important. Therefore, the mean value is more important than the median value in a state where the burden on individuals is reduced by insurance.

Several values of median WTP/QALY are scattered above the 0.5 times line in Fig 3. One possible reason for this is that fewer values of the median were available. That is, the distribution on the lower side (points distributed below 0.5 times) is strongly influenced by the article [31], while the distribution on the upper side contains data extracted from the article [28]. In addition, a previous study has shown that "median values were (predominantly) independent of the size of the utility gain." [38]. Currently, no clear methodology for determining WTP/QALYs has been established, and the median may not be reliable as a basis for real-world practice.

In both the mean and median graphs, the variance of WTP/QALY became larger as GDP per capita increased. This can be expected, as the range of values presented as WTP widens as surplus wealth increases with the growth of GDP.

In this study, only Taiwan was located away from and on the upper side. This is similar to the result in the survey by Shiroiwa et al [28], but the reason for this trend is not clear. Shiroiwa et al (2010) investigated the WTP from the perspective of individual, society, and family, and the results showed that in Western countries, the order of WTP was family > society > individual; in Asian countries, the order was society > family > individual; and in Taiwan, the order was individual > family > society, with the WTP for individuals having the highest value [28]. This unique preference in Taiwan may have affected the present study as well. Furthermore, Taiwan’s implied PPP LCU per USD is about 13, whereas the exchange rate deviates significantly to about 28. This divergence may have affected our results, because PPP and exchange rate rarely diverge significantly.

In the comparison between WTP/QALY and HALE, a statistically significant positive correlation (r = 0.638 p = 0.008) was found when Taiwan was excluded. WTP is correlated with expenditure. Therefore, it can be inferred that when WTP is high, the expenditure on health increases, and this is reflected in HALE. This behavior is in accordance with the Grossman model of the relationship between health and consumption [52]. In addition, since national income level and other factors are considered in setting the threshold, it can be inferred that there is a correlation between CE threshold and HALE.

However, even if a high threshold is set, it is unlikely that the effect will be quickly reflected in healthy life expectancy. In addition, setting unnecessarily high thresholds becomes expensive, and might lead to the collapse of the medical insurance system. This could be avoided by increasing the individual burden and reducing the payers’ burden, but this would result in worsening access to health care resources, hastening the loss of health capital. In many countries, the price of medical care can be adjusted publicly. Therefore, the government can decrease health care costs by lowering prices, but this can be expected to lead to a decline in the quality of services and a delay in research and development of new drugs and new medical devices. However, in Japan Shigeoka et al [53] found that, although price elasticity was reduced by increasing co-payments, this did not affect health. Thus, if out-of-pocket costs are low, it seems likely that costs are excessive and increasing patient out-of-pocket costs could be an effective policy.

The range of estimated WTP/QALYs in the present study can be used as a guide for threshold setting even in countries where no survey of WTP has been conducted. Nevertheless, each country has its own unique circumstances, and thus it is desirable to consider a range of evidence when setting the threshold. The current, widely known WHO criteria seem high when compared to the results of this study. However, greater spending usually means that more medical technology becomes available. Even spending a large amount of money is expected to
improve people’s health and advance the development of medical technology. For this reason, we think that the threshold criteria currently being applied should not be lowered.

This study has several limitations. First is the paucity of available data: not only are there rather few countries in which WTP/QALY surveys have been conducted, but also there is a large variation in the number of surveys across countries. As with many measures, different calculation methods will give different values for WTP/QALYs. It should be possible to reduce the variability by using multiple WTP/QALY values calculated using validated methods and obtaining an average value. Second, factors related to healthy life expectancy include behavior-related factors such as medical visits and treatment and passive factors such as sanitation. Increasing health capital through consumption behavior can be expected to be related to WTP, but the extent to which passive factors are related to WTP is unclear. WTP is correlated with income, and countries with higher income levels can build more advanced infrastructure. However, it cannot be said that there is a direct relationship with WTP, so it is necessary to investigate this issue in the future. Furthermore, the WTP/QALYs in this study are based on the preferences of the general population. They can be used as a reference when setting the threshold, but it should be noted that the relevance to the actual threshold that is set remains uncertain.

In addition, since this survey used only English literature and limited databases, there may be a publication bias. There are also other possible biases due to the scenario in each survey. Previous studies have shown that scenarios can affect WTP/QALY values [8]. Four studies used specific disease scenarios (China, Thailand, USA) [29,43,45,46]. Among them, the Thailand and US studies present lower values. Such studies may tend to have lower values than studies that do not assume a specific disease, such as EQ-5D.

**Conclusion**

Our results suggest that 0.5–1.5 times GDP per capita is appropriate as a threshold setting range for WTP/QALYs. This range is lower than the WHO range (1 to 3 times GDP per capita), but it could be used to set the CE threshold based on consumer preferences. We found a correlation between WTP/QALYs and HALE, which suggests that investment in health is reflected in the outcomes. In the future, as more WTP/QALYs are calculated around the world, this kind of analysis may provide clearer insights for setting policy.

**Supporting information**

S1 Checklist.  
(DOCX)

S2 Checklist.  
(DOCX)

S1 Fig.  
(TIFF)

S2 Fig.  
(PNG)

S1 Table.  
(XLSX)

S2 Table.  
(XLSX)
Acknowledgments
We would like to thank the staff of Keio University Drug Information Laboratory for their cooperation in this study.

Author Contributions
Conceptualization: Haru Iino, Masayuki Hashiguchi.
Data curation: Haru Iino.
Formal analysis: Haru Iino.
Investigation: Haru Iino.
Supervision: Satoko Hori.
Writing – original draft: Haru Iino, Masayuki Hashiguchi.
Writing – review & editing: Haru Iino, Masayuki Hashiguchi, Satoko Hori.

References
1. Center for Outcomes Research and Economic Evaluation for Health. Need for cost-effectiveness evaluation. (In Japanese) [Internet]. [cited 2020 Nov] Available from: https://c2h.niph.go.jp/assessment/necessity/index.html.
2. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013 Mar-Apr; 16(2):231–50. https://doi.org/10.1016/j.jval.2013.02.002 PMID: 23538175.
3. Revill P, Ochalek, Lomas J, Nakamura R, Woods B, Rollinger A et al. Cost-effectiveness thresholds: guiding health care spending for population health improvement.
4. WHO Cost–effectiveness thresholds: pros and cons. [Internet]. [cited 2020 Nov] Available from: https://www.who.int/bulletin/volumes/94/12/15-164418/en/.
5. Woods B, Revill P, Sculpher M, Claxton K. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. Value Health. 2016 Dec; 19(8):929–935. https://doi.org/10.1016/j.jval.2016.02.017 PMID: 27987642; PMCID: PMC5193154.
6. Culyer A. (2016). Cost-effectiveness thresholds in health care: A bookshelf guide to their meaning and use. Health Economics, Policy and Law, 11(4), 415–432. https://doi.org/10.1017/S1744133116000049 PMID: 26906561
7. Nimdet K, Chaikakunapruk N, Vichansavakul K, Ngorsuraches S. A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold? PLoS One. 2015 Apr 9; 10(4): e0122760. https://doi.org/10.1371/journal.pone.0122760 PMID: 25855971; PMCID: PMC4391853.
8. Vallejo-Torres L, García-Lorenzo B, Castilla I, Valcárcel-Nazco C, García-Pérez L, Linertová R et al. On the Estimation of the Cost-Effectiveness Threshold: Why, What, How? Value Health. 2016 Jul-Aug; 19 (5):558–66. https://doi.org/10.1016/j.jval.2016.02.020 Epub 2016 Apr 23. PMID: 27565273.
9. Cameron D, Ubels J, Norström F. On what basis are medical cost-effectiveness thresholds set? Clashings opinions and an absence of data: a systematic review. Glob Health Action. 2018; 11(1):1447828. https://doi.org/10.1080/16549716.2018.1447826 PMID: 29564962; PMCID: PMC5930346.
10. Ryen L, Svensson M. The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature. Health Econ. 2015 Oct; 24(10):1289–1301. https://doi.org/10.1002/hec.3085 Epub 2014 Jul 28. PMID: 25070495.

11. Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan. 2006 Sep; 21(5):402–8. https://doi.org/10.1093/heapol/czl018 Epub 2006 Jul 28. PMID: 16877455.

12. Augustovski F, Colanetinio LD, Galante J, Bardach A, Caporale JE, Zarate V, et al. Measuring the Benefits of Healthcare: DALYs and QALYs—Does the Choice of Measure Matter? A Case Study of Two Preventive Interventions. Int J Health Policy Manag. 2018 Feb 1; 7(2):120–136. https://doi.org/10.15171/ijhpm.2017.47 PMID: 29524936; PMCID: PMC5819372.

13. Pennington M, Baker R, Brouwer W, Mason H, Hansen DG, Robinson A et al. EuroVaQ Team. Comparing WTP values of different types of QALY gain elicited from the general public. Health Econ. 2015 Mar; 24(3):280–93. https://doi.org/10.1002/hec.3018 Epub 2013 Dec 11. PMID: 25625510.

14. Parkin D, Devlin N. Is there a case for using visual analogue scale valuations in cost-utility analysis? Health Econ. 2006 Jul; 15(7):653–64. https://doi.org/10.1002/hec.1086 PMID: 16498700.

15. Torrance GW, Feeny D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making. 2001 Jul-Aug; 21(4):329–34. https://doi.org/10.1177/0272989X0102100408 PMID: 11475389.

16. Gyrd-Hansen D, Kjaer T. Disentangling WTP per QALY data: different analytical approaches, different answers. Health Econ. 2012 Mar; 21(3):222–37. https://doi.org/10.1002/hec.1709 Epub 2011 Jan 20. PMID: 21254305.

17. Calculator USI. US inflation calculator. [Internet]. [cited 2020 Nov] Available from: http://www.usinflationcalculator.com/.

18. International Monetary fund. Implied PPP conversion rate, National currency per international dollar. [Internet]. [cited 2020 Nov] Available from: https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC/ADVEC/WEOWORLD.

19. OECD. Data. Purchasing power parities (PPP) [Internet]. [cited 2021 Dec] Available from: https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm.

20. International Monetary fund. GDP per capita, current prices (Purchasing power parity; international dollars per capita). [Internet]. [cited 2020 Nov] Available from: https://www.imf.org/external/datamapper/PPPPC@WEO/OEMDC/ADVEC/WEOWORLD.

21. World health Organization. Global Health Observatory data repository. Healthy life expectancy (HALE) Data by country. [Internet]. [cited 2020 Nov] Available from: https://apps.who.int/gho/data/node.main.HALE?lang=en.

22. GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10; 392(10159):1859–1922. https://doi.org/10.1016/S0140-6736(18)32335-3 Erratum in: Lancet. 2019 Jun 22;393(10190):e44. PMID: 30415748; PMCID: PMC6252083.

23. World Bank Country and Lending Groups [Internet]. [cited 2021 Dec] Available from: https://blogs.worldbank.org/opendata/new-country-classifications-income-level-2019-2020#:~:text=The%20World%20Bank%20classifies%20the,calculated%20using%20the%20Atlas%20method.

24. statsmodels v0.13.1. statistical models, hypothesis tests, and data exploration. [Internet]. [cited 2021 Dec] Available from: https://www.statsmodels.org/stable/index.html.

25. GitHub: statsmodels. [Internet]. [cited 2021 Dec] Available from: https://github.com/statsmodels/statsmodels.

26. Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Economics. 2018; 27: 746–761. https://doi.org/10.1002/hec.3633 PMID: 29282798.

27. Martín-Fernández J., Polentinos-Castro E., del Cura-González M.I. et al. Willingness to pay for a quality-adjusted life year: an evaluation of attitudes towards risk and preferences. BMC Health Serv Res 14, 287 (2014). https://doi.org/10.1186/1472-6963-14-287 PMID: 24989615.

28. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Baec SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010 Apr; 19(4):422–37. https://doi.org/10.1002/hec.1481 PMID: 19382128.

29. Zhao FL, Yue M, Yang H, Wang T, Wu JH, Li SC. Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis. Med Care. 2011 Mar; 49(3):267–72. https://doi.org/10.1097/MLR.0b013e31820192cd PMID: 21224742.
30. Gyrd-Hansen D. Willingness to pay for a QALY. Health Econ. 2003 Dec; 12(12):1049–60. https://doi.org/10.1002/hec.799 PMID: 14673813.

31. Robinson A, Gyrd-Hansen D, Bacon P, Baker R, Pennington M, Donaldson C; et al. Estimating a WTP-based value of a QALY: the ‘chained’ approach. Soc Sci Med. 2013 Sep; 92:92–104. https://doi.org/10.1016/j.socscimed.2013.05.013 Epub 2013 Jun 4. PMID: 23849283.

32. Mavrodi A, Aletas V. A Contingent Valuation Study for Eliciting a Monetary Value of a Quality-Adjusted Life-Year in the General Greek Population. Value Health Reg Issues. 2020 Sep; 22:36–43. https://doi.org/10.1016/j.vhri.2020.03.002 Epub 2020 Jul 27. PMID: 32731168.

33. Shiroiwa T, Igarashi A, Fukuda T, Ikeda S. WTP for a QALY and health states: More money for severer health states? Cost Eff Resour Alloc. 2013 Sep 1; 11:22. https://doi.org/10.1186/1478-7547-11-22 PMID: 24128004; PMCID: PMC3766196.

34. Igarashi A, Goto R, Yoneyama-Hironzane M. Willingness to pay for QALY: perspectives and contexts in Japan. J Med Econ. 2019 Oct; 22(10):1041–1046. https://doi.org/10.1080/13696998.2019.1639186 Epub 2019 Aug 6. PMID: 31262236.

35. Bobinac A, Van Exel NJ, Rutten FF, Brouwer WB. Willingness to pay for a quality-adjusted life-year: the individual perspective. Value Health. 2010 Dec; 13(8):1046–55. https://doi.org/10.1111/j.1524-4733.2010.00781.x Epub 2010 Sep 3. PMID: 20825620.

36. Bobinac A, van Exel NJ, Rutten FF, Brouwer WB. Valuing QALY gains by applying a societal perspective. Health Econ. 2013 Oct; 22(10):1272–81. https://doi.org/10.1002/hec.2879 Epub 2012 Oct 19. PMID: 23080321.

37. Bobinac A, van Exel J, Rutten FF, Brouwer WB. The value of a QALY: individual willingness to pay for health gains under risk. Pharmacoeconomics. 2014 Jan; 32(1):75–86. https://doi.org/10.1007/s40273-013-0110-1 PMID: 23827957.

38. Bobinac A, van Exel J, Rutten FF, Brouwer WB. GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation. J Health Econ. 2012 Jan; 31(1):158–68. https://doi.org/10.1016/j.jhealeco.2011.09.004 Epub 2011 Oct 1. PMID: 22018622.

39. Song HJ, Lee EK. Evaluation of willingness to pay per quality-adjusted life year for a cure: A contingent valuation method using a scenario-based survey. Medicine (Baltimore). 2018; 97(38):e12453. https://doi.org/10.1097/MD.0000000000001245 PMID: 30235732.

40. Pinto-Prades JL, Loomes G, Brey R. Trying to estimate a monetary value for the QALY. J Health Econ. 2009 May; 28(3):553–62. https://doi.org/10.1016/j.jhealeco.2009.02.003 Epub 2009 Mar 3. PMID: 19137857.

41. Sund B, Svensson M. Estimating a constant WTP for a QALY—a mission impossible? Eur J Health Econ. 2018 Jul; 19(6):781–800. https://doi.org/10.1007/s10198-017-0929-z Epub 2017 Sep 21. PMID: 28932914; PMCID: PMC6008362.

42. Thavorncharoensap M, Leelahavarong P, Doungthipsirkul S et al. Preliminary results “Assessing a societal value for a ceiling threshold in Thailand” 2013. [Internet]. [cited 2020 Nov] Available from: https://www.hitap.net/wp-content/uploads/2020/05/Final-report_WTPQALY.pdf.

43. Thavorncharoensap M, Teerawattananon Y, Natanant S, Kulpeng W, Yothasamut J, Werayingyong P. Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter? Clinicoecon Outcomes Res. 2013; 5:29–36. https://doi.org/10.2147/CEOR.S38062 Epub 2013 Jan 9. PMID: 23435984; PMCID: PMC3548562.

44. Nimdet K, Ngorsuraches S. Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand. BMJ Open. 2015 Oct 5; 5(10):e008123. https://doi.org/10.1136/bmjopen-2015-008123 PMID: 26438139; PMCID: PMC4606417.

45. Byrne MM, O’malley K, Suarez-Almazor ME. Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis. Med Decis Making. 2005 Nov-Dec; 25(6):655–66. https://doi.org/10.1177/0272989X05282636 PMID: 16282216.

46. Lieu TA, Ray GT, Ortega-Sanchez IR, Kleinman K, Rusinak D, Prosser LA. Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster. Pharmacoeconomics. 2009; 27(12):1005–16. https://doi.org/10.2165/11314000-00000000-00000 PMID: 19908925.

47. Il M, Igarashi A, Nakamura R. New Medical Economics: Considering the costs and benefits of medical care (In Japanese) Nippon Hyoron sha co., Ltd. 2019. ISBN: 4535559236, 9784535559233.

48. Teerawattananon Y, Tritasavit N, Suchonwanich N, Kingkaew P. The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand. J Evid Fortbild Qual Gesundhwes. 2014; 106(7):387–404. https://doi.org/10.1016/j.jzefq.2014.06.017 Epub 2014 Aug 23. PMID: 25444298.
49. Teerawattananon Y, Tritasavit N, Suchonwanich N, Kingkaew P. The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand. Z Evid Fortbild Qual Gesundhwes. 2014;108(7):397-404. https://doi.org/10.1016/j.zefq.2014.06.017 PMID: 25444298.

50. National Drug Information [Internet]. [cited 2020 Nov] Available from: http://ndi.fda.moph.go.th/drug_value/index/public/0/60.

51. Ministry of Health, Labour and Welfare. List of items on the National Health Insurance Drug Price List and information on generic drugs. (In Japanese) [Internet]. [cited 2020 Nov] Available from: https://www.mhlw.go.jp/topics/2020/04/tp20200401-01.html.

52. Grossman M. (1972). On the Concept of Health Capital and the Demand for Health. Journal of Political Economy, 80(2), 223–255.

53. Shigeoka H, "The Effect of Patient Cost Sharing on Utilization, Health, and Risk Protection," American Economic Review, American Economic Association, vol. 104(7), pages 2152–84, July 2014.